Kraj: Nowa Zelandia
Język: angielski
Źródło: Medsafe (Medicines Safety Authority)
Pergolide mesilate 0.326mg equivalent to 0.25 mg pergolide
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Pergolide mesilate 0.326 mg (equiv to 0.25 mg pergolide)
0.25 mg
Tablet
Active: Pergolide mesilate 0.326mg equivalent to 0.25 mg pergolide Excipient: Croscarmellose sodium Indigo carmine Iron oxide yellow Lactose monohydrate Magnesium stearate Methionine Povidone
Blister pack, 100 tablets
Prescription
Prescription
Olon SpA
Package - Contents - Shelf Life: Blister pack, - 100 tablets - 24 months from date of manufacture stored at or below 25°C protect from light - Bottle, plastic, HDPE,screw/CRC - 100 tablets - 24 months from date of manufacture stored at or below 25°C protect from light
1991-08-19
PERMAX ® - New Zealand - CMI Page 1 of 4 PERMAX ® _pergolide mesylate _ CONSUMER MEDICINE INFORMATION (CMI) PERMAX CAN CAUSE THE THICKENING OF TISSUE (FIBROTIC REACTIONS) IN AN ORGAN SUCH AS THE LUNGS. PERMAX CAN ALSO DAMAGE THE VALVES OF THE HEART, CAUSING THEM TO LEAK. PLEASE CONSULT YOUR DOCTOR ABOUT REGULAR MONITORING FOR THESE POSSIBLE CONDITIONS. WHAT IS IN THIS LEAFLET This leaflet is designed to provide you with answers to some common questions about PERMAX. It does not contain all the available information and does not take the place of talking with your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of you taking PERMAX against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT PERMAX IS USED FOR PERMAX contains pergolide (as pergolide mesylate) as the active ingredient. It belongs to a group of medicines called ergot derivative dopamine agonists. PERMAX is used to treat Parkinson's disease, a disease of the brain affecting movement. It works by directly stimulating dopamine receptors. It is used in combination with other medicines that treat Parkinson's disease such as Sinemet ® and Madopar ® . It can also be used in patients who have tried unsuccessfully to use a non-ergot medicine. The aim of treatment is to reduce the symptoms and problems associated with Parkinson's disease and to improve your ability to do normal everyday tasks. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY PERMAX HAS BEEN PRESCRIBED FOR YOU. Your doctor may have pre Przeczytaj cały dokument
PERMAX Tablets – Data Sheet Page 1 of 8 PERMAX ® (pergolide mesylate). PERMAX can cause fibrotic reactions and cardiac valvulopathy. Ongoing treatment will require continued monitoring for these adverse events. Pergolide mesylate is an ergot derivative dopamine receptor agonist at D 1 , D 2 and D 3 receptor sites. Pergolide mesylate is chemically designated as 8 ß -[(Methylthio)methyl]-6- propylergoline monomethanesulfonate. The formula weight of the base is 314.5; 1 mg of base corresponds to 3.18 micromol. The CAS number for pergolide is 66104-22-1. Pergolide mesylate has the following structural formula: DESCRIPTION Pergolide mesylate is provided for oral administration in tablets containing 0.05, 0.25, and 1 mg pergolide as the base. The pharmaceutical excipients are lactose, croscarmellose sodium, povidone, magnesium stearate, iron oxide yellow (0.05 and 0.25 mg tablets), methionine (0.05 mg tablet), iron oxide red (1 mg tablet), and indigo carmine - aluminium lake (0.25 mg tablet). CLINICAL PHARMACOLOGY _PHARMACODYNAMIC INFORMATION _ Pergolide is a dopamine receptor agonist which exhibited high _in vitro_ binding affinities for the D 1 , D 2 and D 3 receptors (respective K i values of 180, 33 and 4.2 nM). Pergolide has been shown to be 20 to 200 times more potent than bromocriptine on a milligram for milligram basis _in vivo_. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinising hormone. In Parkinson's disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system. _PHARMACOKINETIC INFORMATION (ABSORPTION, DISTRIBUTION, METABOLISM, Przeczytaj cały dokument